^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Rina-S (rinatabart sesutecan)

    i
    Other names: PRO1184, GEN1184, GEN-1184
    Company:
    Genmab
    Drug class:
    Topoisomerase I inhibitor, Folate receptor 1-targeted antibody-drug conjugate
    Related drugs:
    19d
    RAINFOL-02: An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China (clinicaltrials.gov)
    P3, N=82, Not yet recruiting, Genmab
    New P3 trial • Platinum resistant
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Rina-S (rinatabart sesutecan)
    1m
    RAINFOL-03: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer (clinicaltrials.gov)
    P3, N=660, Recruiting, Genmab | Trial completion date: Feb 2029 --> Nov 2029 | Trial primary completion date: Nov 2028 --> Aug 2029
    Trial completion date • Trial primary completion date
    |
    paclitaxel • doxorubicin hydrochloride • Rina-S (rinatabart sesutecan)
    1m
    RAINFOL-09: Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers (clinicaltrials.gov)
    P2, N=160, Recruiting, Genmab | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rina-S (rinatabart sesutecan)
    1m
    RAINFOL™-07: Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer (clinicaltrials.gov)
    P3, N=688, Not yet recruiting, Genmab
    New P3 trial • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • HRD • BRCA mutation
    |
    Avastin (bevacizumab) • carboplatin • gemcitabine • paclitaxel • Rina-S (rinatabart sesutecan)
    1m
    RAINFOL-05: Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=240, Recruiting, Genmab | N=107 --> 240
    Enrollment change • Trial initiation date
    |
    Rina-S (rinatabart sesutecan)
    2ms
    RAINFOL-09: Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Genmab
    New P2 trial
    |
    Rina-S (rinatabart sesutecan)
    2ms
    RAINFOL-05: Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=62, Recruiting, Genmab
    New P2 trial
    |
    Rina-S (rinatabart sesutecan)
    2ms
    GCT1184-03: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigators Choice in Participants With Endometrial Cancer ( RAINFOL-03 ) (2024-519818-31-01)
    P2/3, N=194, Not yet recruiting, Genmab A/S
    New P2/3 trial
    |
    paclitaxel • doxorubicin hydrochloride • Rina-S (rinatabart sesutecan)
    2ms
    GCT1184-05: Study to assess the efficacy and safety of Rina-S in participants with non-small cell lung cancer (2025-522107-18-00)
    P1/2, N=34, Not yet recruiting, Genmab A/S
    New P1/2 trial
    |
    Neulasta (pegfilgrastim) • Rina-S (rinatabart sesutecan)
    2ms
    GCT1184-03: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigators Choice in Participants With Endometrial Cancer ( RAINFOL-03 ) (2024-519818-31-01)
    P2/3, N=98, Not yet recruiting, Genmab A/S
    New P2/3 trial
    |
    paclitaxel • doxorubicin hydrochloride • Rina-S (rinatabart sesutecan)
    2ms
    GCT1184-03: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigators Choice in Participants With Endometrial Cancer ( RAINFOL-03 ) (2024-519818-31-01)
    P2/3, N=51, Not yet recruiting, Genmab A/S
    New P2/3 trial
    |
    paclitaxel • doxorubicin hydrochloride • Rina-S (rinatabart sesutecan)
    4ms
    RAINFOL-02: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=530, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting
    Enrollment closed • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha ) • BRCA (Breast cancer early onset)
    |
    FOLR1 expression • BRCA mutation
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Rina-S (rinatabart sesutecan)